Finance
AstraZeneca overhauls management of its China division, FT reports
Published by Global Banking & Finance Review®
Posted on January 17, 2025
1 min readLast updated: January 27, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on January 17, 2025
1 min readLast updated: January 27, 2026
AstraZeneca has restructured its China management, appointing Alex Lin as GM and promoting Mary Guan to lead oncology, amid ongoing government probes.
(Reuters) - AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general manager, the Financial Times reported on Friday, citing two people with direct knowledge of the matter.
The Anglo-Swedish drugmaker has promoted Mary Guan to lead oncology in China, according to the report.
AstraZeneca did not immediately respond to a Reuters request for comment.
Last month, the company named Iskra Reic as its new international executive vice president, taking over from Leon Wang, who was detained by Chinese authorities in October.
AstraZeneca said in November that in addition to the Chinese authorities' investigation into Wang, the company is also aware of two separate and ongoing probes by the Chinese government into its activities in the country. One involves suspected medical insurance fraud, and the other relates to the importation of cancer drugs from Hong Kong into mainland China.
(Reporting by Aby Jose Koilparambil in Bengaluru; Editing by Shounak Dasgupta)
The main topic is AstraZeneca's management changes in China amid ongoing government investigations.
Alex Lin has been appointed as the new general manager for AstraZeneca in China.
The probes involve suspected medical insurance fraud and the importation of cancer drugs from Hong Kong into mainland China.
Explore more articles in the Finance category
